Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CCCC vs ANNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANNX Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

ANNX Overall Winner 6-Pillar Tally: CCCC 1 – 4 ANNX (1 Tie) Matrix Metrics: CCCC 3 – 5 ANNX

As of Nov 17, 2026, Annexon, Inc. (ANNX) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CCCC carries a Unified Composite Score of 47.7/100 (HOLD) at $2.53 (N/M Forward P/E, -315.9% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.47 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. ANNX 43.5/100 HOLD), ANNX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -315.9% operating margin) and revenue trajectory (+0.0% vs. -24.6% YoY).
  • Technical & Structure Timing Caution: CCCC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CCCC vs ANNX
CCCC NASDAQ
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.53
-4.53% 1D
Market Cap $362.4M
TTM Revenue $32M
Forward P/E N/M
Beta / 30D Vol 1.48β · 69% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.8%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $3.05 · SMA50: $3.09
ANNX NASDAQ Head-to-Head Winner
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.47
-2.8% 1D
Market Cap $747.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.70β · 63% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 36
RSI-14: 36.3 · SMA20: $3.96 · SMA50: $3.98

6-Pillar Scorecard Institutional Category Breakdown (CCCC 1 – 4 ANNX)

Columns: Metric · CCCC · ANNX
1. Valuation Multiples CCCC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 11.9x N/M
2. Growth & Scale ANNX
Revenue Growth (YoY) -24.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $32M N/A
Market Cap $362.4M $747.8M
3. Profitability & Quality ANNX
Gross Margin 88.8% N/A
Operating Margin -315.9% 0.0%
Net Profit Margin -282.2% 0.0%
Return on Equity (ROE) -47.6% -130.8%
4. Balance Sheet & Cash Flow ANNX
Cash Generation (TTM) -$80M -$190M
Cash Flow Margin N/A N/A
Net Cash / Leverage $23M Net Debt (0.24x D/E) $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 79.8% (3rd %ile) 569.3% (100th %ile)
Put/Call OI Skew 0.41x (Call-Skewed) 0.09x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CCCC (3) vs ANNX (5)
Institutional Metric CCCC ANNX Criterion Row Edge
Market Capitalization
Scale
$362.4M $747.8M Larger Scale ANNX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-24.6% +0.0% Higher Growth ANNX
Operating Margin (TTM)
Profitability
-315.9% 0.0% Higher Margin ANNX
Net Profit Margin
Profitability
-282.2% 0.0% Higher Margin ANNX
Return on Equity (ROE)
Capital Efficiency
-47.6% -130.8% Higher ROE CCCC
52-Week Range Position
Momentum
24% ($2–$5) 18% ($3–$7) Stronger Trend CCCC
Beta / 30D Volatility
Risk Regime
1.48β · 69% Vol 1.70β · 63% Vol Lower Realized Risk ANNX
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite CCCC
Trailing 12M Revenue (USD)
Operating Scale
$32M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
88.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 11.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($23M Net Debt (0.24x D/E)) -$190M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CCCC +1.01 pp
CCCC: -12.46% · ANNX: -13.47%
3M Horizon ANNX +2.99 pp
CCCC: -39.9% · ANNX: -36.91%
6M Horizon CCCC +10.68 pp
CCCC: -18.65% · ANNX: -29.33%
1Y Horizon ANNX +25.61 pp
CCCC: +2.43% · ANNX: +28.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CCCC vs ANNX. Trailing 12-month operating profitability (CCCC -315.9% vs ANNX 0.0%) and valuation multiples (CCCC N/M vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CCCC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$32M
Gross Margin88.8%
Op. Margin-315.9%
ROE / Fwd P/E-47.6% · N/M
ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CCCC BREAKDOWN
118d in phase · OBV DISTRIBUTION
Current IV 79.8%
IV Percentile 3rd %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CCCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANNX BREAKDOWN
88d in phase · OBV DISTRIBUTION
Current IV 569.3%
IV Percentile 100th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CCCC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $362.4M market capitalization and -315.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CCCC vs ANNX Key Questions & Quantitative Answers

As of Nov 17, 2026, Annexon, Inc. (ANNX) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CCCC carries a Unified Composite Score of 47.7/100 (HOLD) at $2.53 (N/M Forward P/E, -315.9% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.47 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. ANNX 43.5/100 HOLD), ANNX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -315.9% operating margin) and revenue trajectory (+0.0% vs. -24.6% YoY). Technical & Structure Timing Caution: CCCC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANNX leads the Growth & Scale pillar: CCCC posts -24.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (88.8% gross margin, -315.9% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CCCC generates $32M in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, CCCC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.

CCCC screens cheaper on headline valuation multiples. CCCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.9x EV/Revenue (unreported FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CCCC (-47.6% ROE) versus ANNX (-130.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CCCC carries 79.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 69% Vol realized risk). By comparison, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.